Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK - PubMed (original) (raw)
. 2013 Apr;1830(4):3067-76.
doi: 10.1016/j.bbagen.2013.01.009. Epub 2013 Jan 16.
Affiliations
- PMID: 23333633
- DOI: 10.1016/j.bbagen.2013.01.009
Up-regulation of miR-182 by β-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK
Chi-Hsiang Chiang et al. Biochim Biophys Acta. 2013 Apr.
Abstract
Background: MiR-182 is a member of the miR-183 cluster located at human chromosome 7q32 region and is up-regulated in human cancers. We study the regulation of miR-182 expression and its oncogenic role.
Methods: MiR-182 level was investigated by real-time reverse transcription-PCR. Chromatin immunoprecipitation assay was used to confirm promoter binding of transcription factors. The correlation between miR-182 and RECK was analyzed by Western blotting, real-time RT-PCR and 3(')-untranslated region reporter assay. Zymography, matrix metalloproteinase activity, invasion and colony formation were used to study the tumorigenic activity.
Results: MiR-182 is over-expressed in human breast tumor tissues and cell lines. Inhibition or knockdown of β-catenin reduced miR-182 level in MDA-MB-231 cells. ChIP assay confirmed the binding of β-catenin on miR-182 promoter. Anti-miR-182 increased the MMP inhibitor RECK protein in MDA-MB-231 cells while pre-miR-182 reduced RECK protein but not mRNA in normal mammary epithelial H184B5F5/M10 cells. Restoration of RECK protein by anti-miR-182 attenuated MMP-9 activity, cell invasion and colony formation. Ectopic expression of miR-182 inhibited restoration of RECK protein by β-catenin inhibitor indicating miR-182 is important for β-catenin-induced down-regulation of RECK. An inverse association between miR-182 and RECK was demonstrated in breast tumor tissues.
Conclusions: We provide evidence that miR-182 is up-regulated by β-catenin signaling pathway in breast cancer and its up-regulation increases tumorigenicity and invasiveness by repressing RECK.
General significance: Our data demonstrate for the first time that miR-182 expression is controlled by β-catenin. In addition, we identify a new miR-182 target RECK which is important for miR-182-induced tumorigenesis.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
- STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells.
Lin HY, Chiang CH, Hung WC. Lin HY, et al. Br J Cancer. 2013 Aug 6;109(3):731-8. doi: 10.1038/bjc.2013.349. Epub 2013 Jul 2. Br J Cancer. 2013. PMID: 23820254 Free PMC article. - miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer.
Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L, Fang L. Zhang J, et al. Oncol Rep. 2014 Mar;31(3):1357-63. doi: 10.3892/or.2013.2934. Epub 2013 Dec 19. Oncol Rep. 2014. PMID: 24366472 - Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity.
Yeh HH, Tseng YF, Hsu YC, Lan SH, Wu SY, Raghavaraju G, Cheng DE, Lee YR, Chang TY, Chow NH, Hung WC, Liu HS. Yeh HH, et al. BMC Cancer. 2015 Mar 25;15:172. doi: 10.1186/s12885-015-1155-7. BMC Cancer. 2015. PMID: 25885317 Free PMC article. - RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling.
Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. Noda M, et al. Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):167-75. doi: 10.1023/a:1023043315031. Cancer Metastasis Rev. 2003. PMID: 12784995 Review. - Transcriptional control of the RECK metastasis/angiogenesis suppressor gene.
Sasahara RM, Brochado SM, Takahashi C, Oh J, Maria-Engler SS, Granjeiro JM, Noda M, Sogayar MC. Sasahara RM, et al. Cancer Detect Prev. 2002;26(6):435-43. doi: 10.1016/s0361-090x(02)00123-x. Cancer Detect Prev. 2002. PMID: 12507228 Review.
Cited by
- MiR-182 promotes proliferation and invasion and elevates the HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7.
Chiang CH, Chu PY, Hou MF, Hung WC. Chiang CH, et al. Am J Cancer Res. 2016 Aug 1;6(8):1785-98. eCollection 2016. Am J Cancer Res. 2016. PMID: 27648365 Free PMC article. - miR-182 targeting reprograms tumor-associated macrophages and limits breast cancer progression.
Ma C, He D, Tian P, Wang Y, He Y, Wu Q, Jia Z, Zhang X, Zhang P, Ying H, Jin ZB, Hu G. Ma C, et al. Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2114006119. doi: 10.1073/pnas.2114006119. Proc Natl Acad Sci U S A. 2022. PMID: 35105806 Free PMC article. - Therapeutic microRNAs in human cancer.
Ors-Kumoglu G, Gulce-Iz S, Biray-Avci C. Ors-Kumoglu G, et al. Cytotechnology. 2019 Feb;71(1):411-425. doi: 10.1007/s10616-018-0291-8. Epub 2019 Jan 1. Cytotechnology. 2019. PMID: 30600466 Free PMC article. Review. - Exosomal miR-182 regulates the effect of RECK on gallbladder cancer.
Zheng H, Wang JJ, Zhao LJ, Yang XR, Yu YL. Zheng H, et al. World J Gastroenterol. 2020 Mar 7;26(9):933-946. doi: 10.3748/wjg.v26.i9.933. World J Gastroenterol. 2020. PMID: 32206004 Free PMC article. - MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9.
Zhang ZF, Wang YJ, Fan SH, Du SX, Li XD, Wu DM, Lu J, Zheng YL. Zhang ZF, et al. Oncotarget. 2017 Sep 22;8(60):101345-101361. doi: 10.18632/oncotarget.21167. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254169 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous